New drug combo offers hope for advanced breast cancer patients
NCT ID NCT03147287
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 24 times
Summary
This study tests three drug combinations for people with a common type of advanced breast cancer (ER+/HER2-) that has stopped responding to initial hormone therapy. About 220 participants will receive either fulvestrant alone, fulvestrant plus palbociclib, or fulvestrant plus palbociclib and avelumab. The goal is to see which combination works best to delay cancer growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aurora Cancer Care
Milwaukee, Wisconsin, 53215, United States
-
Baylor University
Houston, Texas, 77030, United States
-
Boston Medical Center
Boston, Massachusetts, 02188, United States
-
DF/BWCC at Milford Regional Medical Center
Milford, Massachusetts, 01757, United States
-
DF/BWCC in clinical affiliation with South Shore Hospital
South Weymouth, Massachusetts, 02190, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Dana-Farber at St. Elizabeth's Medical Center
Brighton, Massachusetts, 02135, United States
-
Dana-Farber/New Hampshire Oncology-Hematology
Londonderry, New Hampshire, 03053, United States
-
Eastern Maine Medical Center
Bangor, Maine, 04401, United States
-
Emory University - Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
Indiana University
Indianapolis, Indiana, 46202, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
The University of Kansas Cancer Center
Westwood, Kansas, 66205, United States
-
The University of Kansas Cancer Center - Lee's Summit
Lee's Summit, Missouri, 64064, United States
-
The University of Kansas Cancer Center - North
Kansas City, Kansas, 64154, United States
-
The University of Kansas Cancer Center - Overland Park
Overland Park, Kansas, 66210, United States
-
University of Louisville
Louisville, Kentucky, 40202, United States
-
University of Miami
Miami, Florida, 33136, United States
-
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States
-
Washington University
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.